Magnesium.

Your body needs magnesium to switch vitamin D into its active form, so a solid magnesium status helps vitamin D do its job. It is why the two so often share a bottle.

B6 helps magnesium move into cells, and the pair has a long track record together for PMS and for winding down at night.

K2 helps steer calcium into bone rather than the arteries, which is why it rounds out a magnesium and vitamin D bone stack.

The liver and kidney hydroxylase enzymes that convert vitamin D to its 25-hydroxy and 1,25-dihydroxy forms are magnesium dependent, as is the binding protein that carries it in blood. Adequate magnesium status is part of normal vitamin D activation, which is why the two are routinely formulated together.

The sodium potassium ATPase pump that sets cell membrane potential runs on magnesium bound ATP. Magnesium also gates the renal ROMK channel, so normal magnesium status supports the kidney holding on to potassium rather than spilling it into urine.

Calcium and magnesium share intestinal transport routes, so a large calcium dose taken in the same sitting can blunt magnesium uptake. They also act as physiological counterparts at the neuromuscular junction, calcium favouring contraction and magnesium favouring relaxation, which is why splitting the two doses across the day is standard practice.

Zinc and magnesium are both divalent cations absorbed partly through shared paracellular and carrier-mediated routes, so a large single dose of one lowers the absorbed fraction of the other. Splitting the doses across the day is the usual formulation answer.

Ferrous iron and magnesium compete for the same divalent uptake routes in the duodenum, so co-dosing large amounts lowers the absorbed fraction of each. Iron is usually taken separately from a mineral-heavy formula for this reason.

Thiamine has to be phosphorylated to thiamine pyrophosphate by a magnesium-dependent kinase, and the pyrophosphate-using enzymes such as pyruvate dehydrogenase and transketolase also need magnesium. Thiamine cannot do its job while magnesium is short.

The creatine kinase reaction transfers a phosphate between creatine and the magnesium-ATP complex, so magnesium is part of the substrate rather than an accessory. Magnesium status sits directly inside the phosphocreatine shuttle creatine supplies.

Two glycine molecules chelate one magnesium ion into a neutral, low-molecular-weight complex that can use peptide and amino acid uptake routes rather than depending on free cation transport. This is the mechanism behind magnesium bisglycinate.

Carbonate neutralises gastric acid, and magnesium salts need an acidic stomach to dissolve into absorbable ions, so a large carbonate dose lowers magnesium solubility. Calcium also competes with magnesium for the same divalent uptake routes.

Phytic acid in grains and legumes binds magnesium into an insoluble complex the gut cannot absorb, and phytase hydrolyses the phosphate groups that do the binding. Adding phytase to a plant-heavy meal raises the mineral fraction that stays soluble.

Taurine and magnesium both act on the excitability of nerve and muscle membranes, taurine as an osmolyte and modulator of chloride flux, magnesium by damping calcium entry. They are also sold as one salt, magnesium taurate, where taurine is the counter-ion. The pairing is mechanistically coherent; outcome trials of the combination are not what the magnesium literature is built on.

L-theanine influences glutamate and GABA signalling; magnesium sits at the same synapse as a voltage-dependent NMDA channel blocker. The routes differ enough that the effects can stack. Anyone driving or dosing alongside other calming ingredients should count them together.

Valerian constituents act on GABA-A signalling, a different site from magnesium's NMDA channel block, so their calming effects can add rather than compete. This is the practical reason to count total sedating load in an evening stack. It is a pharmacology-level expectation, not a combination trial result.

Passionflower is used for its GABAergic flavonoid content and shows up beside magnesium in night formulas. Additive drowsiness is the expected interaction. No trial in the magnesium candidate set tested the pair.

Chamomile carries apigenin, which binds benzodiazepine-site targets, and it is a long-standing evening drink taken with mineral supplements. Combined calming load is the flag. Evidence for the pairing itself is absent.

Lemon balm is used for its GABA transaminase inhibition and appears in the same evening blends as magnesium. The interaction to expect is additive calm. No combination data sits behind it.

Supplemental GABA and magnesium both end up described in terms of inhibitory tone, though oral GABA's access to the brain is itself contested. If both are taken, count the sedating effect once for the stack rather than per ingredient.

Apigenin binds at benzodiazepine-site targets on GABA-A receptors, a different site from magnesium's block of the NMDA channel. The two are commonly stacked in sleep formulas. Additive drowsiness is the expectation and the caution.

Ashwagandha is used for stress-axis measures while magnesium works at the level of ion handling and enzyme cofactor supply. They sit together in calm-and-sleep products for that reason. The combination itself has not been measured in the studies retrieved here.

Every ATP molecule the respiratory chain produces is used as the magnesium complex Mg-ATP, since kinases and ATPases require the metal to position the phosphate. Coenzyme Q10 carries electrons within that chain. The two sit on the same energy pathway at different points, which is settled biochemistry rather than a tested pairing.

Riboflavin has to be phosphorylated to FMN by riboflavin kinase and then adenylylated to FAD, and both steps run on Mg-ATP. Low magnesium availability therefore limits how much riboflavin becomes usable coenzyme. This is textbook activation chemistry, not an effect claim.

S-adenosylmethionine is made by methionine adenosyltransferase, a magnesium-dependent enzyme that joins methionine to ATP. The body's own SAM-e production therefore depends on magnesium status. Supplemental SAM-e bypasses that step, but the methylation cycle it feeds is still full of magnesium-dependent kinases.

Glutathione is assembled in two ATP-consuming steps, by glutamate-cysteine ligase and glutathione synthetase, and both use Mg-ATP. Magnesium is a requirement for making the tripeptide rather than an antioxidant itself. Taking preformed glutathione does not remove that dependency for endogenous synthesis.

NAC supplies cysteine, the rate-limiting substrate for glutathione, while the two ligation steps that use that cysteine run on Mg-ATP. Substrate and cofactor are different limitations, so covering one says nothing about the other. The mechanism is settled; the combination has not been trialled here.

Nicotinamide mononucleotide adenylyltransferase converts NMN to NAD using ATP, and like other nucleotidyltransferases it needs magnesium to coordinate the phosphates. Magnesium is a cofactor requirement of the pathway, not a booster of it. The claim here is biochemical, not an outcome.

NR is first phosphorylated by nicotinamide riboside kinase, a magnesium-ATP-dependent step, before it can join the NAD pool. Magnesium therefore sits upstream of any NAD precursor's usefulness. This is pathway biochemistry and carries no efficacy claim.

Ribose enters metabolism only after ribokinase phosphorylates it, and that kinase, like essentially all kinases, uses the magnesium complex of ATP. Nucleotide synthesis downstream is similarly magnesium-dependent. The relationship is a cofactor requirement rather than a synergy in effect.

Boron supplementation has been reported to reduce urinary loss of magnesium in human balance studies, which would raise retention without changing intake. Balance measurements are markers of handling, not clinical outcomes. The direction is consistent across the older balance literature but the trial base is small.

Caffeine has a mild diuretic action that increases urinary output of magnesium along with other cations. The loss is modest against normal intake and matters most when intake is already low. This is a handling effect on a status marker, not a reason to avoid either.

High sodium intake raises urinary magnesium loss, because reabsorption of the two is linked along the loop of Henle. Cutting sodium load is one lever on magnesium retention that has nothing to do with the magnesium dose. The evidence is balance and excretion data, so markers rather than outcomes.

Sweat and fluid losses take sodium, potassium, chloride and magnesium together, so replacement products carry them together. Magnesium's share of sweat loss is small next to sodium's, which is why it sits as a minor component. Replacing one cation alone leaves the others where the losses left them.

Manganese and magnesium are both divalent cations that use overlapping transport and can substitute for each other at some enzyme metal sites. High single doses of one taken with the other is where competition would show. At food-level and ordinary supplement intakes this is a theoretical rather than measured concern.

Divalent minerals taken together in a single large dose compete for shared uptake routes in the gut. Copper is present in multiminerals at small amounts, which limits how much competition is possible. Separating a high-dose magnesium from a mineral blend is the practical response if it is a concern.

Large doses of one divalent mineral reduce uptake of another taken at the same moment, which is why iron is usually dosed away from a magnesium or calcium serving. The glycinate chelate reduces but does not remove the overlap, since some of the mineral still dissociates in the gut. Spacing the doses by a couple of hours sidesteps it.

Ferrous salts and magnesium salts taken together compete for uptake, and magnesium-containing antacid salts also raise gastric pH, which works against the acid-dependent absorption of ferrous iron. Both effects push in the same direction. Separate dosing is the standard way it is handled.

Polyphenolic tannins bind divalent cations in the gut lumen and form poorly absorbed complexes. Strong tea and other tannin-rich drinks taken with a mineral dose are the everyday version of this. The chemistry is settled; how much magnesium is lost in practice depends on the amounts of both.

Catechins including EGCG complex divalent minerals, the same chemistry that makes tea a mineral inhibitor at meals. Taking a concentrated catechin extract in the same hour as a magnesium dose is where it matters. The size of the effect on magnesium specifically is not well quantified.

A viscous gel slows the diffusion of dissolved minerals to the absorptive surface and can shift absorption further along the intestine. Whether total magnesium uptake falls depends on transit and the size of the dose. Spacing the fibre from the mineral is a simple way to avoid the question.

Fermentable fructans lower colonic pH and expand the absorptive surface, which has been reported to increase apparent absorption of magnesium and calcium in the large bowel. The measured endpoint is usually apparent absorption or retention, a marker of handling. Gas and bloating at higher fructan doses is the limit on how much of this is usable.

Galactooligosaccharides are fermented to short-chain acids that acidify colonic contents, keeping divalent minerals soluble where they can still be taken up. Reported endpoints are absorption and retention markers. The mechanism is shared with other fermentable fibres rather than specific to GOS.

Resistant starch is fermented in the colon to butyrate and other acids, which lowers luminal pH and keeps magnesium in solution. The link to magnesium retention is inferred from the wider fermentable-fibre literature rather than measured for resistant starch on its own. Read it as a mechanism, not a dosing strategy.

Inositol phosphoglycans act as second messengers in insulin signalling and magnesium is a cofactor for the insulin receptor kinase, so both show up in trials reporting fasting glucose and insulin resistance indices. Those are markers, and neither ingredient has been shown to change the markers by the same route. Anyone tracking blood sugar with medication should count both.

Chromium is studied for insulin signalling measures and magnesium is required by the receptor kinase itself, so their trial readouts overlap on fasting glucose and insulin indices. The overlap is in markers, not in a demonstrated joint outcome. Additive movement in glucose readings is the practical flag when either is added to existing therapy.

Berberine acts through AMPK signalling and magnesium through kinase cofactor supply, and both appear in trials reporting fasting glucose and HbA1c. Effects on those markers could add. Berberine also has its own drug interactions, so the pairing is a monitoring point rather than a recommendation.

Arginine feeds nitric oxide synthesis and magnesium reduces calcium-driven tone in vascular smooth muscle, two different routes to vessel relaxation. Readings taken while both are used can move further than with either alone. This matters most for people already on blood-pressure medication, who should be monitoring anyway.

Citrulline raises plasma arginine and therefore nitric oxide availability, while magnesium acts on smooth muscle calcium handling. The two support normal vessel tone from different angles and their effects on a blood pressure reading can add. Monitoring rather than avoidance is the point of the row.

Dietary nitrate is reduced by oral bacteria to nitrite and then to nitric oxide, lowering vascular resistance; magnesium works on the calcium side of the same smooth muscle. Blood pressure readings can move further with both than with one. Anyone on antihypertensive medication should track the combination.

Silicon is associated with collagen cross-linking in the bone matrix while magnesium sits in the mineral phase itself and is needed for parathyroid hormone secretion and action. They support different halves of bone tissue. Evidence for silicon in humans is thin, so the row stays early.

Strontium substitutes for calcium in the bone mineral lattice and competes with other divalent cations for uptake in the gut. Taking it in the same window as a magnesium or calcium dose reduces absorption of both. Strontium also inflates bone density scans by its atomic weight, so density readings taken during use are not comparable.

A share of high-dose ascorbate is metabolised to oxalate, which appears in urine; magnesium binds oxalate in the gut lumen and reduces how much is absorbed to begin with. The readouts here are urinary chemistry markers, not clinical events. Timing matters, since the binding happens where the two meet in the gut.